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Brief Clinical Reportsversa, particularly when interventional treatments are being
planned.
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Charlottesville, VaThromboembolic events occur in 2% to 3% of patients
receiving the HeartMate II (HMII) left ventricular assist
device (LVAD) (Thoratec Corp, Pleasanton, Calif). Even
though several surfaces of the HMII are textured and throm-
boresistant, long-term anticoagulation is indicated.1 We
report the case of an early postoperative distal inflow-
conduit thrombus resulting in hemolysis in a patient under-
going HMII placement and concomitant bioprosthetic aortic
valve replacement (AVR).CLINICAL SUMMARY
A 61-year-old woman with idiopathic cardiomyopathy, se-
vere aortic stenosis, New York Heart Association class III
heart failure, and a left ventricular ejection fraction of 15%
to 20% (disproportionate to her aortic stenosis) was admitted
for syncope and worsening dyspnea. Her comorbidities
included obesity, diabetes, paroxysmal atrial fibrillation, pre-
vious stroke, and stage III chronic renal insufficiency. An
AVR and HMII LVAD placement were performed, and the
expectation was that the LVAD would serve as a bridge to
recovery or a bridge to transplant. The LVAD insertionand AVR proceeded uneventfully with satisfactory unload-
ing of the left ventricle. Although fastidious surgical hemo-
stasis was achieved, phytonadione, aminocaproic acid, and
multiple blood product transfusions were necessary through
the first 12 hours postoperatively; recombinant factor VIIa
was not required. The patient was extubated within 24 hours
and progressed well. Systemic anticoagulation with warfarin
was initiated within 72 hours (Figure 1).FIGURE 1. Anticoagulation and hemolysis timeline from HMII and AVR
implantation through HMII pump replacement. Vitamin K (dark arrows)
was administered on POD 1 because of suspected hemorrhage/excessive
postoperative bleeding and on POD 26 because of evolving hematomas
around the pump pocket site. Vitamin K was administered on POD 71 to re-
verse therapeutic anticoagulation in preparation for HMII replacement.
Warfarin and ASA administration are identified by grayscale arrows with
the INR trend (dark curve) consistent with warfarin administration. LDH ac-
tivity (data points) remained significantly elevated (dashed regression
trend) with the concomitant haptoglobin level less than 8 mmg/dL through-
out. Taken together, they were suggestive of hemolytic anemia. Regression
trend suggests LDH activity increased with lowered systemic anticoagula-
tion. ASA, Aspirin; AVR, aortic valve replacement; HMII, HeartMate II;
INR, international normalized ratio; LDH, lactate dehydrogenase; OR, oper-
ation; POD, postoperative day; Vit, vitamin; War, warfarin.
ardiovascular Surgery c Volume 140, Number 1 e7
FIGURE 2. Thrombus at the distal end of the inflow-conduit as seen
through the pump body of the HMII. Note the red arrow in the lateral profile
of the HMII LVAD (inset). The inlet bearing cup is identified as the location
of the distal inflow-conduit thrombus. Multiple LVAD studies showed nor-
mal function despite the presence of thrombus, suggesting current modali-
ties may be inadequate to evaluate HMII LVAD pump body lesions. HMII,
HeartMate II; LVAD, left ventricular assist device. (Image use approved by
Thoratec Corp.)
Brief Clinical ReportsThe day before planned discharge (postoperative day 18),
acute-onset hematuria and dyspnea developed. Transthoracic
echocardiography showed occasional opening of the aortic
valve with no paravalvular leak and normal flow into the
LVAD. A large left pleural effusion subsequently developed,
necessitating reintubation. Repeated red blood cell transfu-
sions in response to decreasing hematocrit level led to the
temporary cessation of warfarin. Transesophageal echocardi-
ography with HMII rotor speed adjustments showed expected
variations in left ventricular volume. Cardiac catheterization
with left ventriculography confirmed what appeared to be
normal, but perhaps slightly delayed flow through the
LVAD. There appeared to be no inflow-conduit or outflow-
graft patency limitations. She subsequently had jaundice, he-
moglobinuria, and elevated lactate dehydrogenase (LDH).
Hematologic studies, including von Willebrand factor, glu-
cose-6-phosphate dehydrogenase, fibrinogen, haptoglobin,
and D-dimer levels, suggested ongoing hemolysis. The
LVAD rotor speed was reduced to attenuate any potential me-
chanical source. The HMII controller showed no change in
pump power or differential pressure with a pulsatility index
minimally above expectations.
Owing to ongoing hemolysis, a decision was made to
replace the HMII. Intraoperatively, a thrombus on the inflow
side of the bearing cup was identified (Figure 2). The HMII
pump was replaced and the previously placed inflow-
conduit and outflow-graft were reattached. Systemic antico-
agulation was initiated postoperatively, and an international
normalized ratio of more than 2.0 was maintained. She had
an uneventful postoperative course, was discharged home
within 2 weeks of her second operation, and had made satis-
factory progress at her 3-month follow-up visit.e8 The Journal of Thoracic and Cardiovascular SurgeDISCUSSION
Although thrombus formation is a known late complication
of the HMII,2 early postoperative thrombus formation on the
distal inflow-conduit has not been reported and, in our patient,
was a unique cause of hemolysis. The most widely used anti-
coagulation protocol in patients receiving the HMII is that re-
ported by the Texas Heart Institute.3 The decision to delay
systemic anticoagulation until postoperative day 3 in our pa-
tient was based on postoperative bleeding, coagulopathy, and
the low thromboembolic profile of the HMII. The use of
phytonadione to correct coagulopathy in the face of chronic
renal insufficiency challenges anticoagulation, with the early
use of intravenous phytonadione having a putative delay in
therapeutic systemic anticoagulation. The unclear source of
hemolysis in the face of numerous false-negative LVAD in-
terrogations compounded the difficult diagnosis.
Reportedly, von Willebrand factor–dependent platelet
aggregation and related thrombocytopenia is another poten-
tial source of thrombus.4 On further review of the HMII
pump, the thrombus around the inlet-bearing cup appeared
as a formation of tissue and denatured blood that had under-
gone thermal degradation because of prolonged exposure to
bearing heat. The thrombus demonstrated evidence of lami-
nated layering, indicative of growth over an undetermined
amount of time, presumably in the face of adequate antico-
agulation. The size of the thrombus may have caused nonla-
minar flow to the rotor and subsequent hemolysis.
Absolute anticoagulation requirements after HMII
placement are unclear. One single-center analysis found
the HMII to have an extremely low thromboembolic risk, al-
lowing for less stringent anticoagulation requirements in cer-
tain patients.5 Those at high risk for bleeding can sometimes
be monitored safely with either no or extremely low antico-
agulation requirements.5 We have seen gastrointestinal
bleeding after HMII implantation, requiring cessation of an-
ticoagulation for 2 weeks while the bleeding was managed
with no resultant thrombotic complications. Despite the
low thromboembolic profile of the HMII, early thrombotic
complications such as hemolysis can occur, posing a diag-
nostic challenge.
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